Literature DB >> 17977825

Human papillomavirus E7 requires the protease calpain to degrade the retinoblastoma protein.

Grant A Darnell1, Wayne A Schroder, Toni M Antalis, Eleanore Lambley, Lee Major, Joy Gardner, Geoff Birrell, Angel Cid-Arregui, Andreas Suhrbier.   

Abstract

Cervical cancers transformed by high risk human papilloma virus (HPV) express the E7 oncoprotein, which accelerates the degradation of the retinoblastoma protein (Rb). Here we show that the E7-mediated degradation of Rb requires the calcium-activated cysteine protease, calpain. E7 bound and activated mu-calpain and promoted cleavage at Rb(810), with mutation of this residue preventing E7-mediated degradation. The calpain cleavage product, Rb(1-810), was unable to mediate cell cycle arrest but retained the ability to repress E6/E7 transcription. E7 also promoted the accelerated proteasomal degradation of Rb(1-810). Calpain inhibitors reduced the viability of HPV-transformed cells and synergized with cisplatin. Calpain, thus, emerges as a central player in E7-mediated degradation of Rb and represents a potential new drug target for the treatment of HPV-associated lesions.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17977825     DOI: 10.1074/jbc.M706860200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  16 in total

1.  Role of calpain in the formation of human papillomavirus type 16 E1^E4 amyloid fibers and reorganization of the keratin network.

Authors:  Jameela Khan; Clare E Davy; Pauline B McIntosh; Deborah J Jackson; Steven Hinz; Qian Wang; John Doorbar
Journal:  J Virol       Date:  2011-07-13       Impact factor: 5.103

2.  Nonconserved lysine residues attenuate the biological function of the low-risk human papillomavirus E7 protein.

Authors:  Nicholas J Genovese; Thomas R Broker; Louise T Chow
Journal:  J Virol       Date:  2011-03-16       Impact factor: 5.103

3.  Gene expression profile regulated by the HPV16 E7 oncoprotein and estradiol in cervical tissue.

Authors:  Enoc M Cortés-Malagón; José Bonilla-Delgado; José Díaz-Chávez; Alfredo Hidalgo-Miranda; Sandra Romero-Cordoba; Aykut Uren; Haydar Celik; Matthew McCormick; José A Munguía-Moreno; Eloisa Ibarra-Sierra; Jaime Escobar-Herrera; Paul F Lambert; Daniel Mendoza-Villanueva; Rosa M Bermudez-Cruz; Patricio Gariglio
Journal:  Virology       Date:  2013-09-27       Impact factor: 3.616

Review 4.  The biological properties of E6 and E7 oncoproteins from human papillomaviruses.

Authors:  Raffaella Ghittoni; Rosita Accardi; Uzma Hasan; Tarik Gheit; Bakary Sylla; Massimo Tommasino
Journal:  Virus Genes       Date:  2009-10-17       Impact factor: 2.332

5.  Calpain3 is expressed in a proteolitically active form in papillomavirus-associated urothelial tumors of the urinary bladder in cattle.

Authors:  Sante Roperto; Roberta De Tullio; Cinzia Raso; Roberto Stifanese; Valeria Russo; Marco Gaspari; Giuseppe Borzacchiello; Monica Averna; Orlando Paciello; Gianni Cuda; Franco Roperto
Journal:  PLoS One       Date:  2010-04-22       Impact factor: 3.240

Review 6.  The papillomavirus E7 proteins.

Authors:  Ann Roman; Karl Munger
Journal:  Virology       Date:  2013-05-31       Impact factor: 3.616

7.  The RB tumor suppressor positively regulates transcription of the anti-angiogenic protein NOL7.

Authors:  Tanmayi P Mankame; Mark W Lingen
Journal:  Neoplasia       Date:  2012-12       Impact factor: 5.715

Review 8.  The human papillomavirus oncoproteins: a review of the host pathways targeted on the road to transformation.

Authors:  James A Scarth; Molly R Patterson; Ethan L Morgan; Andrew Macdonald
Journal:  J Gen Virol       Date:  2021-01-11       Impact factor: 3.891

Review 9.  Oncogenic potential of Human Papillomavirus (HPV) and its relation with cervical cancer.

Authors:  Rabia Faridi; Amreen Zahra; Khalida Khan; Muhammad Idrees
Journal:  Virol J       Date:  2011-06-03       Impact factor: 4.099

Review 10.  Virus-Driven Carcinogenesis.

Authors:  Yuichiro Hatano; Takayasu Ideta; Akihiro Hirata; Kayoko Hatano; Hiroyuki Tomita; Hideshi Okada; Masahito Shimizu; Takuji Tanaka; Akira Hara
Journal:  Cancers (Basel)       Date:  2021-05-27       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.